CEO resigned + possibility of a board restructuring with recent major shareholder general meeting request + EBIT of 22 to 26 million for a 646m company (at 6.68 per share)
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%